根据诺和诺德公司周三公布的一项基于真实世界数据的研究分析，那些从肥胖治疗注射剂转为使用诺和诺德的新药Wegovy片剂的患者在三个月后仍持续减轻体重。
People who switched from obesity injections to Novo 's new Wegovy pill continued to lose weight after three months, according to an analysis of real-world data the company presented on Wednesday.
真实世界研究主要用于评估各种治疗手段之间的关联性，无法确定其中的因果关系。但研究结果表明，Wegovy片剂可能比注射剂更能帮助患者维持已减掉的体重（而不仅仅是初期阶段的体重减轻效果）。此外，这也意味着患者可能无需长期接受每周一次的注射治疗（如Wegovy或Zepbound），而是可以选择更便捷的口服药物作为替代方案。
Real-world studies evaluate associations and can't determine causality. But the results suggest that the Wegovy pill may improve upon the initial weight loss people experience on blockbuster injections rather than simply maintain it. It also suggests that patients may not need to take weekly shots like Wegovy and Zepbound forever, and can instead opt for more convenient treatments such as Novo's pill.
诺和诺德的分析使用了来自Ro公司远程医疗平台的数据，研究对象为194名肥胖或超重患者，其中约56%为女性。其中一半患者最初使用的是诺和诺德的Wegovy注射剂，另一半则使用的是礼来公司的Zepbound注射剂。
Novo's analysis used data from Ro's telehealth platform on 194 patients with obesity or who were overweight, around 56% of whom were female. Half started on Novo's Wegovy injection and the rest initially took Eli Lilly 's shot Zepbound.
那些从注射剂转为Wegovy片剂并持续接受治疗三个月的患者，平均体重减轻了约4%（相当于额外减掉了8.8磅）。诺和诺德表示，这些患者的初始平均体重约为221磅。
Patients who switched from an injection to the Wegovy pill and stayed on treatment for three months lost roughly 4% of their weight, or an additional 8.8 pounds, on average. That's based on an average starting weight of around 221 pounds before taking the pill, Novo said.
在所有参与者中，有五分之二的患者在转为Wegovy片剂三个月后体重减轻了5%或更多。同时，在转为Wegovy片剂三个月后，BMI（身体质量指数）达到或超过30的患者比例下降了21%以上；BMI达到30意味着一个人已经从超重状态进入了肥胖状态。
Of those participants, 2 in 5 achieved 5% or more weight loss three months after switching to the pill. Meanwhile, the share of people with a body mass index at or above 30 decreased by more than 21% three months after switching to oral Wegovy. A BMI of 30 shifts a person from the overweight category into obesity.
诺和诺德首席科学官马丁·霍尔斯特·朗格（Martin Holst Lange）在接受采访时说：“我们的产品具有独特优势：目前市场上，皮下注射的Wegovy可以与口服Wegovy片剂互换使用，患者可以期待获得相同的耐受性和安全性，并且还能实现更高的体重减轻效果——而这正是许多患者所期望的。”
"We have the unique benefit that, in the market, the subcutaneous Wegovy can now be interchanged with a tablet of Wegovy, and the patient can expect the same tolerability profile, the same safety profile, and actually a little bit more weight loss, which is what a lot of them want," Martin Holst Lange, Novo's chief scientific officer, said in an interview.
在有可用数据的患者中，约82%报告称，在服用该药期间至少有一项改善。其中，近70%表示衣服穿得更合身，约51%表示开始采取更健康的饮食方式。
Among patients with available data, around 82% reported at least one improvement during treatment with the pill. That includes almost 70% who reported better-fitting clothes and around 51% who said they pursued healthier eating.
据诺和诺德称，在该分析中，约75%的患者表示满意于改用口服药。
Around 75% of patients in the analysis said they were satisfied with the switch to a pill, according to Novo.
兰格说：“我认为，我们正在看到一种转变。就在大约一年前，我们还以为绝大多数希望接受肥胖治疗的患者都满意于皮下注射治疗。现在，我们对这种情况有了不同的认识。我们明显看到，患者更偏好口服药。”他还指出，有些经常出差或旅行的人，不愿操心注射药物的冷藏问题。
"I think we are seeing a shift where we, maybe just a year ago, we actually thought that the vast majority of patients who wanted treatment for obesity were happy with a subcutaneous treatment," Lange said. "We see that picture differently now. We clearly see a preference for orals." He pointed to people who travel a lot and don't want to think about refrigerating their injections.
这是首批有关患者从畅销注射药物转向新型口服药后减重结果的真实世界证据之一，尤其是从诺和诺德的Wegovy注射剂和礼来的竞品Zepbound转向该口服药。但诺和诺德表示，该研究的局限包括常规远程医疗过程中采集数据的时间点和完整性存在差异，自我报告的数据可能存在偏差，研究结果“无法推广至更广泛的人群”。
It is among the first real-world evidence of weight loss outcomes among patients switching from blockbuster injections, particularly Novo's Wegovy shot and Lilly's rival Zepbound, to the new pill. But the study's limitations include variable timing and completeness of the data collected during routine telehealth care, self-reported data being subject to bias and results "not being generalizable to the broader population," Novo said.
这些数据也是诺和诺德本周在欧洲糖尿病研究协会于意大利米兰举行的会议上发布的若干新数据集之一，内容涉及其肥胖和糖尿病研发管线。
The figures are also one of several new datasets Novo is unveiling this week on its obesity and diabetes pipeline at the European Association for the Study of Diabetes in Milan, Italy.
诺和诺德还在周三宣布，其实验性下一代肥胖药物CagriSema能够减少“食物噪音”，即持续不断的食物相关念头，并有助于器官和骨骼健康。这一结论来自一项为期一年的功能磁共振成像研究结果。功能磁共振成像是一种在执行特定任务时测量大脑活动的无创方法。
Also on Wednesday, Novo announced that its experimental next-generation obesity drug CagriSema reduced "food noise" — persistent thoughts about food — and showed benefits in organ and bone health. That's based on results from a yearlong functional magnetic resonance imaging study, which is a noninvasive method to measure brain activity during specific tasks.
CagriSema是诺和诺德的司美格鲁肽与一种名为卡格列肽的药物的组合；前者是Wegovy的活性成分，后者以胰淀素为靶点。CagriSema预计将于明年初上市，随后在2028年推出单独使用的卡格列肽以及更高剂量的CagriSema。
CagriSema is a combination of Novo's semaglutide — the active ingredient in Wegovy — and a drug called cagrilintide that targets amylin. CagriSema is expected to launch early next year, followed by standalone cagrilintide and a higher-dose version of CagriSema in 2028.
在该研究中，诺和诺德表示，CagriSema改变了肥胖或超重人群的大脑对诱人、高热量食物的反应，这种变化涉及与食欲渴望、愉悦感和自我控制有关的脑区。
In the study, Novo said CagriSema changed how the brain reacted to tempting, high-calorie foods in areas linked to cravings, pleasure and self-control in people with obesity or who were overweight.
“大脑中的信号会发生改变，而且这种改变确实与生活质量的提升有关，”兰格说。
"The signal in the brain changes in a way that actually is associated with improved quality of life," said Lange.
公司补充称，CagriSema减少了2型糖尿病成年患者腹部器官周围的有害脂肪，包括肝脏和胰腺中的脂肪。诺和诺德指出，初步结果还显示，尽管患者大幅减重，但其骨骼健康仍得到了维持。
The company added that CagriSema reduced harmful fat around abdominal organs, including in the liver and pancreas, in adults with Type 2 diabetes. Early findings also suggest that patients' bone health was maintained despite substantial weight loss, Novo noted.
这家药品制造商表示，研究结果表明，CagriSema可能从大脑以及多个器官和组织层面着手，处理肥胖和糖尿病的潜在根源因素，而非仅仅影响体重和血糖水平。
The drugmaker said the findings suggest CagriSema may address underlying factors of obesity and diabetes in the brain and multiple organs and tissues, rather than only impacting weight and blood sugar levels.
在 Google 上将 CNBC 设为您的首选来源，不错过商业新闻领域最值得信赖的品牌所报道的每一个重要时刻。
Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.